• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于分段定量分析的被动传递,首次证明 daprodustat 和其他缺氧诱导因子稳定剂被整合到马毛中。

First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.

机构信息

Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi 320-0851, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan.

Drug Analysis Department, Laboratory of Racing Chemistry, 1731-2 Tsuruta-machi, Utsunomiya, Tochigi 320-0851, Japan.

出版信息

J Pharm Biomed Anal. 2023 Oct 25;235:115600. doi: 10.1016/j.jpba.2023.115600. Epub 2023 Jul 24.

DOI:10.1016/j.jpba.2023.115600
PMID:37516063
Abstract

Daprodustat is a hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitor and is used as an erythropoiesis stimulant for the treatment of anemia in humans. In general, administering daprodustat to horses will result in a lifetime ban from both equestrian sports and horseracing by the International Federation of Horseracing Authorities and the Fédération Équestre Internationale, respectively. To control the misuse/abuse of daprodustat, we conducted nasoesophageal administration of daprodustat (100 mg/day for 3 days) to three thoroughbred mares and the post-administration hair samples collected from the three horses over 6 months were analyzed to demonstrate the potential longer-term detection of daprodustat and its metabolites in hair compared with the detection times of daprodustat of 1 and 2 weeks in plasma and urine respectively. The results of the quantitative 2-cm segmental analysis showed that daprodustat was primarily localized in the proximal region (0-2 cm) at 0.375-0.463 pg/mg at 1 month post-administration. These drug bands were gradually spread out along the hair shaft at a rate consistent with the reported growth rate of horse mane hair (approximately 2.5 cm/month) over the following 6 months. In addition, to attain deeper insight into the mechanism of drug incorporation into hair, a total of 11 relevant parameters, including the actual PK parameters and simulated physicochemical and biopharmaceutical parameters for three HIF stabilizers (i.e., daprodustat, vadadustat, and IOX4), were investigated after normalization of the z-scores of all these parameters. Multiple regression analysis indicated that the major factors contributing to the incorporation of the three drugs into hair were their maximum plasma concentrations and lipophilicities, strongly suggesting that the three HIF stabilizers permeated from the bloodstream into the hair bulb via passive transfer with concentration gradients. This work is the first reported evidence showing the incorporation of HIF stabilizers into hair via passive transfer. In addition, cross-species comparison of drug incorporations into hair between daprodustat in horse and roxadustat in human was made in order to have a better understanding of the interactive interpretations about the analysis results obtained from different species. The above findings are not only useful and beneficial for the purpose of doping control but also provide a better understanding of the mechanism of drug incorporation into horse hair.

摘要

达普司他是一种低氧诱导因子脯氨酰羟化酶结构域(HIF-PHD)抑制剂,被用作人类贫血的促红细胞生成刺激剂。一般来说,国际赛马组织联盟和国际马术联合会分别禁止向马匹施用达普司他,否则涉事马匹将被终生禁止参加赛马和马术运动。为了控制达普司他的滥用,我们向三匹纯种母马进行了鼻腔内给药(连续 3 天,每天 100mg),并分析了这三匹马在给药后 6 个月内采集的毛发样本,以证明与血浆中达普司他的检测时间(分别为 1 周和 2 周)相比,毛发中达普司他及其代谢物的潜在长期检测结果。2cm 分段分析的定量结果表明,给药后 1 个月,达普司他主要定位于近端区域(0-2cm),浓度为 0.375-0.463pg/mg。这些药物带沿着毛干逐渐扩散,速度与马鬃毛的报告生长速度(约每月 2.5cm)一致,在接下来的 6 个月内。此外,为了更深入地了解药物掺入毛发的机制,对 3 种 HIF 稳定剂(即达普司他、vadadustat 和 IOX4)的 11 个相关参数(包括实际 PK 参数和模拟的理化和生物制药参数)进行了总计研究,所有这些参数的 z 分数均归一化。多元回归分析表明,导致三种药物掺入毛发的主要因素是其最大血浆浓度和脂溶性,这强烈表明三种 HIF 稳定剂通过被动转移和浓度梯度从血液渗透到毛球。这项工作是首次报道 HIF 稳定剂通过被动转移掺入毛发的证据。此外,还对马中的达普司他和人中的罗沙司他在毛发中的药物掺入情况进行了种间比较,以便更好地理解从不同物种获得的分析结果的交互解释。上述发现不仅对兴奋剂控制具有有益的作用,还提供了对马毛发中药物掺入机制的更好理解。

相似文献

1
First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.基于分段定量分析的被动传递,首次证明 daprodustat 和其他缺氧诱导因子稳定剂被整合到马毛中。
J Pharm Biomed Anal. 2023 Oct 25;235:115600. doi: 10.1016/j.jpba.2023.115600. Epub 2023 Jul 24.
2
Long-term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometry for the purpose of doping control.利用液相色谱/电喷雾电离 Q Exactive 高分辨质谱法对马毛进行 IOX4 的长期监测及其分段分析,目的是进行兴奋剂控制。
Drug Test Anal. 2022 Jul;14(7):1244-1254. doi: 10.1002/dta.3247. Epub 2022 Mar 7.
3
Segmental analysis and long-term monitoring of vadadustat in equine hair for the purpose of doping control.分段分析和长期监测马毛中的vadadustat,以达到兴奋剂控制的目的。
J Anal Toxicol. 2023 Sep 15;47(7):623-631. doi: 10.1093/jat/bkad057.
4
In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.缺氧诱导因子脯氨酰羟化酶抑制剂 daprodustat、desidustat 和 vadadustat 的体外研究用于马的兴奋剂控制。
Drug Test Anal. 2022 Feb;14(2):317-348. doi: 10.1002/dta.3188. Epub 2021 Nov 25.
5
The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.比较非透析慢性肾脏病患者肾性贫血治疗中vadadustat 和 daprodustat 的剂量、成本和安全性。
Intern Med. 2024 Jul 1;63(13):1855-1861. doi: 10.2169/internalmedicine.2501-23. Epub 2023 Nov 6.
6
Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control.采用液相色谱/电喷雾电离 Q Exactive 高分辨质谱联用仪对马尿液和血浆中的 IOX4 进行全面代谢研究,以进行兴奋剂控制。
Drug Test Anal. 2022 Feb;14(2):233-251. doi: 10.1002/dta.3172. Epub 2021 Oct 21.
7
Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?达普司他相较于促红细胞生成素刺激剂(ESAs)在治疗慢性肾脏病(CKD)相关贫血方面是否具有优势?
Expert Opin Pharmacother. 2022 May;23(7):769-773. doi: 10.1080/14656566.2022.2060078. Epub 2022 Apr 5.
8
Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHIs)治疗慢性肾脏病相关性贫血的疗效比较:透析和非透析依赖人群的网状荟萃分析
Clin Kidney J. 2023 Dec 7;17(1):sfad298. doi: 10.1093/ckj/sfad298. eCollection 2024 Jan.
9
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.缺氧诱导因子脯氨酰羟化酶抑制剂治疗慢性肾脏病贫血的长期疗效和安全性:一项包含 13146 名患者的荟萃分析。
J Clin Pharm Ther. 2021 Aug;46(4):999-1009. doi: 10.1111/jcpt.13385. Epub 2021 Feb 21.
10
Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control.在赛马兴奋剂控制目的下,对vadadustat 的药代动力学研究及其在马属动物中新型代谢物的高分辨质谱特征分析。
Curr Drug Metab. 2022;23(10):850-865. doi: 10.2174/1389200223666220825093945.

引用本文的文献

1
Quantification of osilodrostat in horse urine using LC/ESI-HRMS to establish an elimination profile for doping control.采用 LC/ESI-HRMS 定量检测马尿液中的奥斯利定,建立赛马兴奋剂检测的消除谱。
Bioanalysis. 2024;16(17-18):947-958. doi: 10.1080/17576180.2024.2385848. Epub 2024 Sep 5.
2
Simultaneous detection of three hypoxia-inducible factor stabilizers-molidustat, roxadustat, and vadadustat-in multiple keratinized matrices and its application in a doping context.在多种角化基质中同时检测三种缺氧诱导因子稳定剂——莫利司他、罗沙司他和瓦达司他——及其在兴奋剂检测中的应用。
Drug Test Anal. 2025 May;17(5):647-654. doi: 10.1002/dta.3771. Epub 2024 Jul 11.